Put companies on watchlist
Edwards Lifesciences
ISIN: US28176E1082
WKN: 936853
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Edwards Lifesciences · ISIN: US28176E1082 · PR Newswire (ID: 20241112PH54824)
12 November 2024 11:03PM

EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit


BENSALEM, Pa., Nov. 12, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW).

Class Period: February 6, 2024July 24, 2024

Lead Plaintiff Deadline: December 13, 2024

Investors suffering losses on their Edwards Lifesciences investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 215-638-4847 or by email to howardsmith@howardsmithlaw.com.

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) the Company did not possess reliable information pertaining to projected revenue outlook and anticipated growth; (2) the Company's growth was at risk of decelerating; (3) the Company's "patient activation activities" failed to reach the perceived low-treatment-rate population TAVR's growth relied upon obtaining; (4) the Company overstated hospital desire to continue to utilize the Company's TAVR procedures over newer, innovative structural heart therapies; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847 or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847

howardsmith@howardsmithlaw.com

www.howardsmithlaw.com

Cision View original content:https://www.prnewswire.com/news-releases/ew-investors-have-opportunity-to-lead-edwards-lifesciences-corporation-securities-fraud-lawsuit-302303164.html

SOURCE Law Offices of Howard G. Smith

Visual performance / price development - Edwards Lifesciences
Smart analysis and research tools can be found here.
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2024
PR Newswire
Contact:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942